Operation Ramsay

Ramsay Healthcare (RHC) presents a unique investment opportunity.

In April, KKR, a mammoth private equity firm that has USD $439 billion in assets under management, led a consortium of investors to submit a AUD $88.00 per share or $20.1 billion bid to purchase Ramsay Healthcare.  The bid represented a 36.7% premium to Ramsay’s share price at the time.

An ageing population coupled with the current healthcare crisis, has made Ramsay an attractive takeover target as demand for the services of Australia’s largest private hospital operator is only going to strengthen in the future.

Ramsay is well-established worldwide, having hospitals, day surgery units, private care services and specialist clinics that deal with outpatients across four regions:

  • Australia – largest private hospital operator that owns the likes of Pindara and John Flynn Private Hospitals on the Gold Coast.
  • Europe – major presence in Denmark, Norway, France and Sweden making Ramsay one of Europe’s leaders in private hospitalisation and primary care.
  • UK – has a network of day procedure centres and 34 acute hospitals where patients receive short-term treatment for a severe injury or illness, an urgent medical condition, or during recovery from surgery.
  • Asia – its presence in this region is limited but Ramsay still owns three hospitals in Indonesia and a nursing college in Malaysia.

Over its four regions, Ramsay employs approximately 86,000 people and attends to over 8 million patient every year across its 532 facilities.

Ramsay’s share price is currently trading at approximately $70.00 per share, representing a potential upside of 25% to KKR’s takeover offer of $88.00 per share.  The reason Ramsay is trading at a discount to the offer price is doubt over whether the takeover will proceed.

KKR has an ownership stake in Elsan – a French hospitals group that is a direct competitor with Ramsay Santé (a subsidiary of Ramsay Healthcare and the largest private hospitalisation provider in France). The issue affecting the takeover is the need for KKR to do its due diligence of Ramsay Santé. This is unlikely to happen as Ramsay will not divulge information to a direct competitor.

Investment banks, Goldman Sachs and UBS, are working on a solution to avoid the need for KKR to gain access to Ramsay Santés books. It seems as if Ramsay Santé will be spun off and KKR will purchase the remainder of Ramsay’s business including the Australian division which provides the bulk of Ramsay’s earnings.

As we see it, the takeover will either be accepted and shareholders will be the beneficiary of a 25% increase in the share price or the takeover offer will get rejected, leaving investors owning a quality asset with long-term and sustainable growth projected.

Buy last sale $70.50

General Advice Warning
The information provided in this post is general information only. Unless otherwise stated the information is not designed for the purpose of providing personal, financial or investment advice. Any examples are presented for illustration purposes and past performance is not a reliable indicator of future performance. The information provided does not take into account your particular investment objectives, financial situation or investment needs.

Without limiting the generality of the above paragraph no person, persons or organisation should invest monies or take action on the reliance of the material contained in this post, but instead should satisfy themselves independently (whether by expert advice or otherwise) of the appropriateness of any such action. Unless otherwise stated the information presented is not a recommendation to invest in any investments, securities or financial products.

This service, like all other financial services, is subject to market forces and unpredictable events that may adversely affect its future performance. Whilst all care has been taken in compiling information in this post, and is provided in good faith, it is not to be relied upon as a substitute for professional advice. The views expressed are commentary only and the writer accepts no responsibility for the accuracy, completeness or timeliness of the information.

Super Equity Pty Ltd ACN 609 373 202 is a Corporate Authorised Representative 001238425 of ANDIKA Pty Ltd AFSL 297069. It should also be noted that references and hyperlinks to any third party information (including, but not limited to: news articles, blogs, reports, videos or other mediums of information) is not an endorsement of that party or product.